$FibroGen (FGEN.US)$ NEWS FIBROGEN ANNOUNCES CLINICAL DATA F...
NEWS
FIBROGEN ANNOUNCES CLINICAL DATA FROM DOSE ESCALATION PHASE 1B STUDY OF FG-3246 (FOR46) IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER WILL BE PRESENTED AT THE 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment